1 / 55

New Frontier in the Management of Venous Thromboembolic Disease (VTE) ACCP Guidelines 2012

New Frontier in the Management of Venous Thromboembolic Disease (VTE) ACCP Guidelines 2012. Samer Koussayer, MD, FACS. Asst Professor , Al Faisal University Section Head and consultant Vascular & Endovascular Surgery Division King Faisal Specialist Hospital @ Research Center Riyadh, KSA.

miracle
Download Presentation

New Frontier in the Management of Venous Thromboembolic Disease (VTE) ACCP Guidelines 2012

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. New Frontier in the Management of Venous Thromboembolic Disease (VTE)ACCP Guidelines 2012 Samer Koussayer, MD, FACS. Asst Professor , Al Faisal University Section Head and consultant Vascular & Endovascular Surgery Division King Faisal Specialist Hospital @ Research Center Riyadh, KSA

  2. Case Report • 52-year-old male was referred to us with enlarging thoracoabdominal aortic aneurysm Type3 (extending from the midthoracic aorta to the aortic bifurcations) • C/O: severe leg claudication and back pain. • PMH: • Severe COPD. • stroke with mild right hemiparesis and slurred speech. • hypertension, diabetes and epilepsy .

  3. Work up • CTA: • Large Type III TAAA (6.5cm) . • Thrombosis of IR portion of TAAA and both CIA. • Stenosis of celiac artery, Patent SMA. • Left renal artery occlusion with atrophic left kidney. • Right renal stenosis • Normal creatinine level.

  4. CTA RT Renal Artery stenosis Atrophic LT Kidney Thrombosis of IRAAA

  5. CTA

  6. Aortobifemoral Bypass Graft Aorto-Renal & Aorto-Celiac/SMA Bypass

  7. Anastomosis of the graft to the Celiac Artery

  8. Anastomosis of the graft to SMA & RT Renal artery

  9. Postoperatively • No kidney dysfunction • No stroke. • No paraplegia. • He was placed on prophylactic dose of Clexan.

  10. Postoperative Day # 3 • (2:00 am): sudden progressive hypoxemia , Chest x-ray showed a picture of oligemia over the right lung • diagnosis of acute pulmonary embolism was entertained. • The patient was switched from Clexan to Heparin infusion

  11. Postoperative Day # 3 ECG showed diffuse T-inversions in precordial leads. Troponin increased from normal to 0.14. Further imaging studies to confirm the diagnosis of PE were not possible due to unstable circulatory condition of the patient. Died secondary to Massive pulmonary embolism

  12. ACCP Evidence-Based Clinical Practice Guidelines 9th Ed. 2012 ACCP: American College of Chest Physician

  13. Endorsing Organizations • This guideline has received the endorsement of the following organizations: • American Association of Clinical Chemistry • American College of Clinical Pharmacy • American Society of Health System Pharmacists • American Society of Hematology • International Society of Thrombosis andHemostasis

  14. ACCP Grading System • The strength of any recommendation depends on two factors: - The trade-off between benefits, risks, burdens, costs, and level of confidence in estimates of those benefits and risks - The quality of the evidence upon which the recommendations are based • If benefits outweigh risks, burdens, and costs, a strongrecommendationis used (Grade 1) . • If there is less certainty about magnitude of benefits and risks, burdens, and costs, a weakrecommendation is used (Grade 2) . • Evidence for recommendations: • high-quality (A), moderate-quality (B), or low-quality (C). • The phrase “we recommend” is used for strong recommendations (Grade 1A, 1B, 1C) and “we suggest” for weak recommendations (Grade 2A, 2B, 2C).

  15. DVT

  16. Parenteral Anticoagulation Prior to Receipt of the Results of Diagnostic of VTE • In patients with a low clinical suspicion of acute DVT, we suggest nottreating with parenteral anticoagulants while awaiting the results of diagnostic tests, provided test results are expected within 24 h(Grade 2C). • In patients with a high clinical suspicion of acute DVT, we suggest treatment with parenteral anticoagulants compared with no treatment while awaiting the results of diagnostic tests (Grade 2C).

  17. Anticoagulation in Patients With Isolated Distal DVT • In patients with acute isolated distal DVT(Tibio-peronealVeins)andwithoutsevere symptoms or risk factors for extension: • Wesuggest serial imaging of the deep veins for 2 weeks (Grade 2C). • If the thrombus does not extend, we recommend no anticoagulation (Grade 1B) • If the thrombus extends: • but remains confined to the distal veins, we suggest anticoagulation (Grade 2C) • into the proximal veins, we recommend anticoagulation (Grade 1B).

  18. Anticoagulation in Patients With Isolated Distal DVT • In patients with acute isolated distal DVT of the leg and with severe symptoms or risk factors for extension: • we suggest initial anticoagulation over serial imaging of the deep veins(Grade 2C). • we recommend using the same approach as for patients with acute proximal DVT (Grade 1B).

  19. Choice of Initial Anticoagulant Regimen in Patients With Proximal DVT • In patients with acute DVT of the leg: • we suggest LMWH or fondaparinux over IV or SC UFH (Grade 2C) • we suggest once- over twice-daily LMWH administration (Grade 2C). • In patients with acute DVT of the leg and whose home circumstances are adequate, we recommend initial treatment at home over treatment in hospital (Grade 1B).

  20. Timing of Initiation of VKA • We recommend initial treatment with parenteral anticoagulation (LMWH, fondaparinux, IV UFH, or SC UFH) (Grade 1B). • We recommendearly initiation of VKA (eg, sameday asparenteraltherapy is started), and continuation ofparenteralanticoagulation for a minimum of 5days and until the international normalized ratio (INR) is 2.0 or above for at least 24 h(Grade 1B). • We recommend a therapeutic INR range of 2.0 to 3.0 (target INR of 2.5) for all treatment durations (Grade 1B).

  21. Intervention for Patients With Acute Proximal DVT • Wesuggestanticoagulant therapy alone: • over catheter-directed thrombolysis (CDT) (Grade 2C). • over systemic thrombolysis(Grade 2C). • over operative venous thrombectomy(Grade 2C). • If patients have had any method of thrombus removal, we recommend the same intensity and duration of anticoagulant therapy as in comparable patients who do not undergo thrombosis removal (Grade 1B).

  22. Early Ambulation of Patients With Acute DVT • In patients with acute DVT of the leg: • we suggest early ambulation over initial bed rest (Grade 2C). • we suggest the use of compression stockings (Grade B2). • we suggest that venoactive medications (eg, rutosides, defibrotide, and hidrosmin) not be used (Grade 2C).

  23. Choice of Anticoagulant Regimen for Long-term Therapy • In patients with DVT of the leg and no cancer: • we suggest VKA therapy over LMWH for long-term therapy (Grade 2C). • If not treated with VKA therapy, we suggest LMWH over dabigatran or rivaroxaban for long-term therapy(Grade 2C). • In patients with DVT of the leg and cancer: • we suggest LMWH over VKA therapy (Grade 2B). • If not treated with LMWH, we suggest VKA over dabigatran or rivaroxaban for long-term therapy (Grade 2B).

  24. Duration of Long-term Anticoagulant Therapy • In patients with a proximal DVT(above the knee) provokedby surgery or nonsurgical transient risk factor : • we recommend (Grade 1B) treatment with anticoagulation for 3 months over: • (i) treatment of a shorter period • (ii) treatment of a longer time-limited period (eg, 6 or 12 months) • (iii) extended therapy (regardless of bleeding risk).

  25. Duration of Long-term Anticoagulant Therapy • In patients with anunprovoked First DVTof the leg (isolated distal or proximal) we recommend treatment with anticoagulation for at least 3 months(Grade 1B). • After 3 months of treatment : • Proximal DVT • low or moderate bleeding risk, we suggest extended anticoagulant therapy over 3 months of therapy(Grade 2B). • high bleeding risk, we recommend 3 months of anticoagulant therapy only (Grade 1B). • Isolated distal DVT • we suggest 3 months of anticoagulant therapyonly(Grade1B).

  26. Duration of Long-term Anticoagulant Therapy • In patients with a secondunprovoked VTE: • we recommend extended anticoagulant therapy over 3 months of therapy in those who have a low bleeding risk (Grade 1B), or moderate bleeding risk(Grade 2B) • we suggest 3 months of anticoagulant therapy only in those who have high bleeding risk (Grade 2B).

  27. Asymptomatic DVT of the Leg In patients who are incidentally found to have asymptomatic DVT of the leg, we suggest the same initial and long-term anticoagulation as for comparable patients with symptomatic DVT (Grade 2B).

  28. Treatment of Patients With Superficial Vein Thrombosis • In patients with superficial vein thrombosis of the lower limb of at least5 cm in length, wesuggestthe use of a prophylactic dose offondaparinux (2.5 mg daily) or LMWH for 45 days over no anticoagulation (Grade 2B).

  29. Pulmonary Embolism ( PE )

  30. Parenteral Anticoagulation Prior to Receipt of the Results of Diagnostic Workup for PE • In patients with alowclinical suspicion of acute PE: • we suggestnot treating with parenteral anticoagulants while awaiting the results of diagnostic tests, provided test results are expected within 24 h (Grade 2C). • In patients with anintermediateclinical suspicion of acute PE: • we suggest treatment with parenteral anticoagulants, if the results of diagnostic tests are expected to be delayed for more than 4 h (Grade 2C). • In patients with ahighclinical suspicion of acute PE: • we suggest treatment with parenteral anticoagulants • while awaiting the results of diagnostic tests (Grade 2C).

  31. Systemic Thrombolytic • Acute PE not associated with hypotension: • we recommend against systemically administered thrombolytic therapy (Grade 1C). • In selected patients with a low bleeding risk whose initial clinical presentation, or clinical course after starting anticoagulant therapy, suggests a high risk of developing hypotension, we suggest administration of thrombolytic therapy (Grade 2C). • Acute PE with hypotension: (eg, systolic BP < 90 mm Hg) • we suggest systemically administered thrombolytic therapy(Grade 2C). • when a thrombolytic agent is used we suggest short infusion times (eg, a 2-h infusion) over prolonged infusion times (eg, a 24-h infusion) (Grade 2C). • we suggest administration through a peripheral vein over a pulmonary artery catheter (Grade 2C).

  32. Acute PE Associated with Hypotension • In patients with acute PE associated with hypotension and who have: • contraindications to thrombolysis, • failed thrombolysis, or • shock that is likely to cause death before systemic thrombolysis can take effect (eg, within hours) • we suggest catheter-assisted thrombus removal(Grade 2C). • If catheter-assisted embolectomy failed, we suggest surgical pulmonary embolectomy provided surgical expertise and resources are available (Grade 2C).

  33. Length Of The Treatment • Patients with afirst unprovoked PE: • we recommend treatment with anticoagulation for at least 3 months(Grade 1B). • After 3 months of treatment, patients should be evaluated for the risk-benefit ratio of extended therapy: • who have a low or moderate bleeding risk, we suggest extended anticoagulant therapy over 3 months of therapy (Grade 2B). • who have a high bleeding risk, we recommend 3 months of anticoagulant therapy only (Grade 1B).

  34. Length Of The Treatment • Patients with a second unprovoked PE: • low bleeding risk, we recommend extended anticoagulant therapy over 3 months of therapy (Grade 1B) • moderate bleeding risk, we suggest extended anticoagulant therapy (Grade 2B). • high bleeding risk, we suggest 3 months of therapy only (Grade 2B). • In patients who are incidentally found to have asymptomatic PE, we suggest the same initial and long- term anticoagulation as for comparable patients with symptomatic PE (Grade 2B).

  35. Length Of The Treatment • If PE provoked by surgery or nonsurgical transient risk factor: • we recommend treatment with anticoagulation for 3 months over (Grade 1B) • treatment of a shorter period, • treatment of a longer time-limited period (eg, 6 or 12 months), or • extended therapy.

  36. Vena Cava Filters for the Initial Treatment of Patients With PE or DVT • Patients with acute PE or DVT who are treated with anticoagulants, we recommend against the use of an IVC filter (Grade 1B). • Patients with contraindication to anticoagulation, we recommendthe use of an IVC filter (Grade 1B). • In patients who has IVC filter inserted as an alternative to anticoagulation, • we suggest a conventional course of anticoagulant therapy if their risk of bleeding resolves (Grade 2B). • We do not consider that a permanent IVC filter, of itself, is an indication for extended anticoagulation.

  37. Upper Extremity DVT ( UEDVT )

  38. ACCP Guidelines for Patients With UEDVT • In patients with UEDVT that involves the axillary or more proximal veins: • we recommend acute treatment with parenteral anticoagulation (Grade 1B) • we suggest LMWH or fondaparinux over IV or SC UFH (Grade 2B). • we suggest anticoagulant therapy alone overthrombolysis(Grade 2C). • we suggest a minimum duration of anticoagulation of 3 months over a shorter period (Grade 2B).

  39. Thrombolytic Therapy for the Initial Treatment of Patients With UEDVT In patients with UEDVT who undergo thrombolysis, we recommend the same intensity and duration of anticoagulant therapy as in similar patients who do not undergo thrombolysis(Grade 1B).

  40. UEDVT and Central Venous Catheter • Patients with UEDVT that is associated with a central venous catheter: • we suggest that the catheter notbe removed if it is functional and there is an ongoing need for the catheter (Grade 2C). • we recommend that anticoagulation is continued as long as the central venous catheter remains over stopping after 3 months of treatment(Grade 1C). • If the central venous catheter was removed, then we recommend3 months of anticoagulation over a longer duration of therapy in patients(Grade 1B)

  41. Splanchnic & Hepatic Veins

  42. ACCP Guidelines • In patients with symptomaticsplanchnic vein thrombosis (portal, mesenteric, and/or splenic vein thromboses), we recommend anticoagulation over no anticoagulation (Grade 1B). • In patients with symptomatic hepatic vein thrombosis, we suggest anticoagulation over no anticoagulation (Grade 2C). • In patients with incidentally detected splanchnic vein or hepatic vein thrombosis, we suggestno anticoagulation over anticoagulation (Grade 2C).

  43. Renal Vein Thrombosis (RVT) • Etiology • Idiopathic, malignancy (Renal Cell Carcinoma), nephrotic syndrome, infection, post-operative, dehydration, IBS, hormone therapy, thrombophilia • Presentation • Asymptomatic often until renal failure, abdominal pain, hematuria • Therapy: • Nephrectomy is usually not recommended • Anticoagulation – no RCT data, but observed CrCl improvement

  44. Summary • we suggest once- over twice-daily LMWH • In patients with acute DVT of the leg and whose home circumstances are adequate, we recommend initial treatment at home • We recommendearly initiation of VKA (same day as parenteral therapy is started) over delayed initiation, and continuation of parenteral anticoagulation for a minimum of 5 days and until the (INR) is 2.0 or above for at least 24 h

More Related